These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11988481)

  • 1. Matrix metalloproteinases: are they antiatherogenic but proaneurysmal?
    Bendeck MP
    Circ Res; 2002 May; 90(8):836-7. PubMed ID: 11988481
    [No Abstract]   [Full Text] [Related]  

  • 2. Reduced atherosclerotic plaque but enhanced aneurysm formation in mice with inactivation of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene.
    Silence J; Collen D; Lijnen HR
    Circ Res; 2002 May; 90(8):897-903. PubMed ID: 11988491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased medial degradation with pseudo-aneurysm formation in apolipoprotein E-knockout mice deficient in tissue inhibitor of metalloproteinases-1.
    Lemaître V; Soloway PD; D'Armiento J
    Circulation; 2003 Jan; 107(2):333-8. PubMed ID: 12538437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New insights into the world of matrix metalloproteinases.
    Ferrans VJ
    Circulation; 2002 Jan; 105(4):405-7. PubMed ID: 11815418
    [No Abstract]   [Full Text] [Related]  

  • 5. [Role of matrix metalloproteinases in aneurysmatic aortic disease].
    Troisi N; Mazza A; Mazza F; Iannelli G
    Monaldi Arch Chest Dis; 2004 Sep; 62(3):169-75. PubMed ID: 15633908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Matrix metalloproteinases; the past, present, and future].
    Yana I; Seiki M
    Nihon Shokakibyo Gakkai Zasshi; 2003 Feb; 100(2):144-51. PubMed ID: 12649853
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of deletion of the tissue inhibitor of matrix metalloproteinases-1 gene on the progression of murine thoracic aortic aneurysms.
    Ikonomidis JS; Gibson WC; Butler JE; McClister DM; Sweterlitsch SE; Thompson RP; Mukherjee R; Spinale FG
    Circulation; 2004 Sep; 110(11 Suppl 1):II268-73. PubMed ID: 15364874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Matrix metalloproteinases and atherosclerosis. Therapeutic aspects].
    Beaudeux JL; Giral P; Bruckert E; Foglietti MJ; Chapman MJ
    Ann Biol Clin (Paris); 2003; 61(2):147-58. PubMed ID: 12702469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypertension does not account for the accelerated atherosclerosis and development of aneurysms in male apolipoprotein e/endothelial nitric oxide synthase double knockout mice.
    Chen J; Kuhlencordt PJ; Astern J; Gyurko R; Huang PL
    Circulation; 2001 Nov; 104(20):2391-4. PubMed ID: 11705813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic backgrounds but not sizes of atherosclerotic lesions determine medial destruction in the aortic root of apolipoprotein E-deficient mice.
    Shi W; Brown MD; Wang X; Wong J; Kallmes DF; Matsumoto AH; Helm GA; Drake TA; Lusis AJ
    Arterioscler Thromb Vasc Biol; 2003 Oct; 23(10):1901-6. PubMed ID: 12920047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth.
    Luttun A; Lutgens E; Manderveld A; Maris K; Collen D; Carmeliet P; Moons L
    Circulation; 2004 Mar; 109(11):1408-14. PubMed ID: 14993123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinase system deficiencies and matrix degradation.
    Lijnen HR; Collen D
    Thromb Haemost; 1999 Aug; 82(2):837-45. PubMed ID: 10605791
    [No Abstract]   [Full Text] [Related]  

  • 13. Matrix metalloproteinases and abdominal aortic aneurysms: a potential therapeutic target.
    Sinha S; Frishman WH
    J Clin Pharmacol; 1998 Dec; 38(12):1077-88. PubMed ID: 11301559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein E knockout mice over-expressing human tissue inhibitor of metalloproteinase 1 are protected against aneurysm formation but not against atherosclerotic plaque development.
    Cuaz-Pérolin C; Jguirim I; Larigauderie G; Jlassi A; Furman C; Moreau M; Chapman MJ; Fruchart JC; Slimane MN; Mezdour H; Rouis M
    J Vasc Res; 2006; 43(6):493-501. PubMed ID: 16931892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T cell control of extracellular matrix degradation.
    St-Pierre Y; Potworowski EF
    Dev Immunol; 2000; 7(2-4):171-7. PubMed ID: 11097210
    [No Abstract]   [Full Text] [Related]  

  • 16. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives.
    Beaudeux JL; Giral P; Bruckert E; Foglietti MJ; Chapman MJ
    Clin Chem Lab Med; 2004 Feb; 42(2):121-31. PubMed ID: 15061349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential applications of matrix metalloproteinase inhibitors in geriatric practice.
    Marder G; Greenwald RA
    Isr Med Assoc J; 2003 May; 5(5):361-4. PubMed ID: 12811957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracellular proteolysis in the development and progression of atherosclerosis.
    Lijnen HR
    Biochem Soc Trans; 2002 Apr; 30(2):163-7. PubMed ID: 12023844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysosomal cysteine proteases in atherosclerosis.
    Liu J; Sukhova GK; Sun JS; Xu WH; Libby P; Shi GP
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1359-66. PubMed ID: 15178558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced expression of matrix metalloproteinase-3, -12, and -13 mRNAs in the aortas of apolipoprotein E-deficient mice with advanced atherosclerosis.
    Jeng AY; Chou M; Sawyer WK; Caplan SL; Von Linden-Reed J; Jeune M; Prescott MF
    Ann N Y Acad Sci; 1999 Jun; 878():555-8. PubMed ID: 10415771
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.